Article | Published:

Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders

Neuropsychopharmacologyvolume 43pages18051812 (2018) | Download Citation



Prior work suggests a role of kappa-opioid signaling in the control of alcohol drinking, in particular when drinking is escalated due to alcohol-induced long-term neuroadaptations. Here, we examined the small molecule selective kappa antagonist CERC-501 in rat models of alcohol-related behaviors, with the objective to evaluate its potential as a candidate therapeutic for alcohol use disorders. We first tested the effect of CERC-501 on acute alcohol withdrawal-induced anxiety-like behavior. CERC-501 was then tested on basal as well as escalated alcohol self-administration induced by 20% alcohol intermittent access. Finally, we determined the effects of CERC-501 on relapse to alcohol seeking triggered by both stress and alcohol-associated cues. Control experiments were performed to confirm the specificity of CERC-501 effects on alcohol-related behaviors. CERC-501 reversed anxiety-like behavior induced by alcohol withdrawal. It did not affect basal alcohol self-administration but did dose-dependently suppress self-administration that had escalated following long-term intermittent access to alcohol. CERC-501 blocked relapse to alcohol seeking induced by stress, but not when relapse-like behavior was triggered by alcohol-associated cues. The effects of CERC-501 were observed in the absence of sedative side effects and were not due to effects on alcohol metabolism. Thus, in a broad battery of preclinical alcohol models, CERC-501 has an activity profile characteristic of anti-stress compounds. Combined with its demonstrated preclinical and clinical safety profile, these data support clinical development of CERC-501 for alcohol use disorders, in particular for patients with negatively reinforced, stress-driven alcohol seeking and use.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010;1314:44–55.

  2. 2.

    Crowley NA, Kash TL. Kappa opioid receptor signaling in the brain: circuitry and implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2015;62:51–60.

  3. 3.

    Morris BJ, Haarmann I, Kempter B, Hollt V, Herz A. Localization of prodynorphin messenger rna in rat brain by in situ hybridization using a synthetic oligonucleotide probe. Neurosci Lett. 1986;69:104–8.

  4. 4.

    Hurd YL, Svensson P, Ponten M. The role of dopamine, dynorphin, and CART systems in the ventral striatum and amygdala in cocaine abuse. Ann N Y Acad Sci. 1999;877:499–506.

  5. 5.

    Heilig M, Schank JR. Kappa-opioid receptor antagonism: a mechanism for treatment of relief drinking? Biol Psychiatry. 2014;75:750–1.

  6. 6.

    Walker BM, Valdez GR, McLaughlin JP, Bakalkin G. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol. 2012;46:359–70.

  7. 7.

    Marinelli PW, Quirion R, Gianoulakis C. A microdialysis profile of beta-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration. Psychopharmacology. 2003;169:60–67.

  8. 8.

    Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008;33:643–52.

  9. 9.

    Marinelli PW, Bai L, Quirion R, Gianoulakis C. A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2005;29:1821–8.

  10. 10.

    Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 1992;89:2046–50.

  11. 11.

    Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther. 1993;264:489–95.

  12. 12.

    Rose JH, Karkhanis AN, Chen R, Gioia D, Lopez MF, Becker HC et al. Supersensitive kappa opioid receptors promotes ethanol withdrawal-related behaviors and reduce dopamine signaling in the nucleus accumbens. Int J Neuropsychopharmacol. 2016;19:pyv127.

  13. 13.

    Heilig M, Egli M, Crabbe JC, Becker HC. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol. 2010;15:169–84.

  14. 14.

    Meinhardt MW, Sommer WH. Postdependent state in rats as a model for medication development in alcoholism. Addict Biol. 2015;20:1–21.

  15. 15.

    Kissler JL, Sirohi S, Reis DJ, Jansen HT, Quock RM, Smith DG, et al. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry. 2014;75:774–82.

  16. 16.

    Berger AL, Williams AM, McGinnis MM, Walker BM. Affective cue-induced escalation of alcohol self-administration and increased 22-kHz ultrasonic vocalizations during alcohol withdrawal: role of kappa-opioid receptors. Neuropsychopharmacology. 2013;38:647–54.

  17. 17.

    Harshberger E, Gilson EA, Gillett K, Stone JH, El Amrani L, Valdez GR. nor-BNI antagonism of kappa opioid agonist-induced reinstatement of ethanol-seeking behavior. J Addict. 2016;2016:1084235.

  18. 18.

    Walker BM, Zorrilla EP, Koob GF. Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict Biol. 2011;16:116–9.

  19. 19.

    Beardsley PM, Pollard GT, Howard JL, Carroll FI. Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. Psychopharmacology. 2010;210:189–98.

  20. 20.

    Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, et al. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem. 2007;282:29803–11.

  21. 21.

    Butelman ER, Yuferov V, Kreek MJ. kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012;35:587–96.

  22. 22.

    Zhou L, Stahl EL, Lovell KM, Frankowski KJ, Prisinzano TE, Aube J, et al. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPgammaS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting. Neuropharmacology. 2015;99:131–41.

  23. 23.

    Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, et al. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol. 2004;501:111–9.

  24. 24.

    Schank JR, Goldstein AL, Rowe KE, King CE, Marusich JA, Wiley JL, et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol. 2012;17:634–47.

  25. 25.

    Buda JJ, Carroll FI, Kosten TR, Swearingen D, Walters BB. A double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of single, escalating oral doses of JDTic. Neuropsychopharmacology. 2015;40:2059–65.

  26. 26.

    Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131–44.

  27. 27.

    Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, et al. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol. 2014;54:968–78.

  28. 28.

    Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, et al. Receptor occupancy of the kappa-opioid antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050. J Pharmacol Exp Ther. 2016;356:260–6.

  29. 29.

    Reed B, Butelman ER, Fry R, Kimani R, Kreek MJ. Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence. Neuropsychopharmacology. 2017;43:739–750.

  30. 30.

    Augier E, Dulman RS, Singley E, Heilig M. A method for evaluating the reinforcing properties of ethanol in rats without water deprivation, saccharin fading or extended access training. J Vis Exp. 2017.

  31. 31.

    Augier E, Flanigan M, Dulman RS, Pincus A, Schank JR, Rice KC, et al. Wistar rats acquire and maintain self-administration of 20 % ethanol without water deprivation, saccharin/sucrose fading, or extended access training. Psychopharmacology. 2014;231:4561–8.

  32. 32.

    Carnicella S, Ron D, Barak S. Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse. Alcohol. 2014;48:243–52.

  33. 33.

    Carnicella S, Yowell QV, Ron D. Regulation of operant oral ethanol self-administration: a dose-response curve study in rats. Alcohol Clin Exp Res. 2011;35:116–25.

  34. 34.

    Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R, et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res. 2008;32:1816–23.

  35. 35.

    Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, et al. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci. 2007;27:2718–26.

  36. 36.

    Tejeda HA, Hanks AN, Scott L, Mejias-Aponte C, Hughes ZA, O’Donnell P. Prefrontal cortical kappa opioid receptors attenuate responses to amygdala inputs. Neuropsychopharmacology. 2015;40:2856–64.

  37. 37.

    Valenza M, Butelman ER, Kreek MJ. “Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”. Psychopharmacology. 2017;234:2219–31.

  38. 38.

    Andrews ZB, Grattan DR. Opioid receptor subtypes involved in the regulation of prolactin secretion during pregnancy and lactation. J Neuroendocrinol. 2003;15:227–36.

  39. 39.

    Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther. 1999;288:260–9.

  40. 40.

    Krulich L, Koenig JI, Conway S, McCann SM, Mayfield MA. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488. Neuroendocrinology. 1986;42:82–87.

  41. 41.

    Wilhelm J, Heberlein A, Karagulle D, Groschl M, Kornhuber J, Riera R, et al. Prolactin serum levels during alcohol withdrawal are associated with the severity of alcohol dependence and withdrawal symptoms. Alcohol Clin Exp Res. 2011;35:235–9.

  42. 42.

    Hillemacher T, Frieling H, Bayerlein K, Wilhelm J, Kornhuber J, Bleich S. Biological markers to predict previous alcohol withdrawal seizures: a risk assessment. J Neural Transm. 2007;114:151–4.

  43. 43.

    Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci. 1984;7:223–55.

  44. 44.

    Redila VA, Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology. 2008;200:59–70.

  45. 45.

    Carey AN, Borozny K, Aldrich JV, McLaughlin JP. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. Eur J Pharmacol. 2007;569:84–89.

  46. 46.

    Lindholm S, Werme M, Brene S, Franck J. The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res. 2001;120:137–46.

  47. 47.

    Cashman JR, Azar MR. Potent inhibition of alcohol self-administration in alcohol-preferring rats by a kappa-opioid receptor antagonist. J Pharmacol Exp Ther. 2014;350:171–80.

  48. 48.

    Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131–44.

  49. 49.

    Doyon WM, Howard EC, Shippenberg TS, Gonzales RA. Kappa-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration. Neuropharmacology. 2006;51:487–96.

  50. 50.

    Mitchell JM, Liang MT, Fields HL. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacol (Berl). 2005;182:384–92.

  51. 51.

    Kovacs KM, Szakall I, O’Brien D, Wang R, Vinod KY, Saito M, et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res. 2005;29:730–8.

  52. 52.

    Racz I, Markert A, Mauer D, Stoffel-Wagner B, Zimmer A. Long-term ethanol effects on acute stress responses: modulation by dynorphin. Addict Biol. 2013;18:678–88.

  53. 53.

    Siciliano CA, Calipari ES, Cuzon Carlson VC, Helms CM, Lovinger DM, Grant KA, et al. Voluntary ethanol intake predicts kappa-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques. J Neurosci. 2015;35:5959–68.

  54. 54.

    Picker MJ, Mathewson C, Allen RM. Opioids and rate of positively reinforced behavior: III. Antagonism by the long-lasting kappa antagonist norbinaltorphimine. Behav Pharmacol. 1996;7:495–504.

  55. 55.

    Broadbear JH, Negus SS, Butelman ER, de Costa BR, Woods JH. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacol (Berl). 1994;115:311–9.

  56. 56.

    Liu X, Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci. 2002;22:7856–61.

  57. 57.

    Knoll AT, Carlezon WA Jr.. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73.

  58. 58.

    Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–16.

  59. 59.

    Carlezon WA Jr., Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016;33:895–906.

Download references


We thank Dr. Ron Marcus and Drs. Natalie Farries of Cerecor INc., Baltimore, MD for their collaboration and CERC-501 supply.


This research was supported by funding from the Swedish Research Council and a grant from Cerecor Inc.

Author information


  1. Department of Clinical and Experimental Medicine, Center for Social and Affective Neuroscience, Linköping University, Linköping, Sweden

    • E Domi
    • , E Barbier
    • , E Augier
    • , G Augier
    • , R Barchiesi
    • , A Thorsell
    • , L Holm
    •  & M Heilig
  2. Cerecor, Baltimore, MD (DG) and Matrix Pharmaceutical Consulting, Boulder, CO, United States

    • D Gehlert


  1. Search for E Domi in:

  2. Search for E Barbier in:

  3. Search for E Augier in:

  4. Search for G Augier in:

  5. Search for D Gehlert in:

  6. Search for R Barchiesi in:

  7. Search for A Thorsell in:

  8. Search for L Holm in:

  9. Search for M Heilig in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to M Heilig.

Electronic supplementary material

About this article

Publication history